% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

  • no_icarus no_icarus Feb 11, 2014 9:58 AM Flag

    Label expansion strategy(!!) in tomorrows investor presentation (INSMED website)

    Thanks Biowatchdog!

    June is not that far away

    eCTD will be filed in a couple of weeks and the CF Pa filing with EMA will be in 3-4 months.
    CF Pa extension initial results.
    They will be broadening delivery…podhaler?
    Label expansion strategy.

    “ Most resistance to aminoglycosides is caused by bacterial inactivation by intracellular enzymes. Because of structural differences, amikacin is not inactivated by the common enzymes that inactivate gentamicin and tobramycin. Therefore, a large proportion of the gram-negative aerobes that are resistant to gentamicin and tobramycin are sensitive to amikacin. In addition, with increased use of amikacin, a lower incidence of resistance has been observed compared with increased use of gentamicin and tobramycin.”

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
13.27+0.07(+0.53%)Aug 30 4:00 PMEDT